Clinical Pharmacokinetics

, Volume 40, Issue 6, pp 473–483

Pharmacokinetics of Cyclosporin Microemulsion in Patients with Inflammatory Bowel Disease

  • Miriam Latteri
  • Giulia Angeloni
  • Nicola Gentiloni Silveri
  • Raffaele Manna
  • Giovanni Gasbarrini
  • Pierluigi Navarra
Original Research Article



To obtain a pharmacokinetic profile of cyclosporin microemulsion formulation in patients with inflammatory bowel disease.

Patients and participants

58 consecutive patients (19 women and 39 men), aged 16 to 64 years (mean age 38 years), with a diagnosis of ulcerative colitis (29 patients) or Crohn’s disease (29 patients).


Patients were treated with oral doses of cyclosporin microemulsion ranging from 200 to 400mg daily. Blood samples were collected after 7 days of treatment; blood was drawn at 0, 0.5, 1, 2, 3, 5, 7 and 12 hours after the morning dose. In 23 patients out of 29 with ulcerative colitis and 23 out of 29 with Crohn’s disease, these profiles were repeated immediately before hospital discharge, which took place an average of 18 days after admission. Blood specimens were assayed for cyclosporin immunoreactivity on the day of blood withdrawal by a radioimmunoassay technique.

Main outcome measures and results

In the range of doses employed, the average peak plasma drug concentration (Cmax) and area under the concentration-time curve to 12 hours tended to increase linearly with the dose (from 782.35 to 1607.98 μg/L and from 3612 to 7221 μg · h/L for doses of 200mg and 400mg, respectively), whereas the time to Cmax (tmax) and elimination half-life (t½β) ranged between 78 and 95.2 min and 85.5 and 162 min, respectively, and did not appear to change with the dose. After dose-normalisation by transformation of data into percentage increase over baseline (trough) concentration for each patient, single kinetic parameters for the whole study population (n = 58) could be calculated (Cmax 620% vs baseline, tmax 86.5 min, t½β 115 min). Comparison between patients with Crohn’s disease and ulcerative colitis showed that the latter had higher Cmax values (702% compared with 543% vs baseline, p < 0.05) whereas tmax and t½β values overlapped.


The pharmacokinetic parameters of cyclosporin microemulsion in patients with inflammatory bowel disease are broadly similar to those previously measured in healthy volunteers and in other disorders requiring cyclosporin treatment.


  1. 1.
    Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28(2): 297–321PubMedCrossRefGoogle Scholar
  2. 2.
    Michetti P, Peppercorn MA. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am 1999; 28(2): 353–70PubMedCrossRefGoogle Scholar
  3. 3.
    Hanauer SB. Drug therapy: inflammatory bowel disease. N Engl J Med 1996; 334: 841–8PubMedCrossRefGoogle Scholar
  4. 4.
    Habal FM, Kirkpatrick A, Greenberg GR. Long term safety of 5-aminosalicylic acid in inflammatory bowel disease: a seven year follow-up. Am J Gastroenterol 1994; 89: A 1691Google Scholar
  5. 5.
    Robinson M. Medical therapy of inflammatory bowel disease for the 21st century. Eur J Surg 1998; Suppl. 582: 90–8Google Scholar
  6. 6.
    Lamers CB, Griffioen G, van Hogezand RA, et al. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 111–5PubMedGoogle Scholar
  7. 7.
    Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993; 696: 9–19PubMedCrossRefGoogle Scholar
  8. 8.
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5PubMedCrossRefGoogle Scholar
  9. 9.
    Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41(12): 2471–6PubMedCrossRefGoogle Scholar
  10. 10.
    Wenzl HH, Petritsch W, Aichbichler BW, et al. Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis. Z Gastroenterol 1998; 36: 287–93PubMedGoogle Scholar
  11. 11.
    Brynskov J, Freund L, Norby Rasmussen S, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 1989; 321: 845–50PubMedCrossRefGoogle Scholar
  12. 12.
    Brynskov J, Freund L, Norby Rasmussen S, et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn’s disease. Scand J Gastroenterol 1991; 26: 689–95PubMedCrossRefGoogle Scholar
  13. 13.
    Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with intravenous cyclosporin A. Am J Gastroenterol 1993; 88: 646–9PubMedGoogle Scholar
  14. 14.
    Santos JV, Baudet JA, Casellas FJ, et al. Intravenous cyclosporine for steroid-refractory attacks of Crohn’s disease. J Clin Gastroenterol 1995; 20: 207–10PubMedCrossRefGoogle Scholar
  15. 15.
    Ramakrishna J, Langhans N, Calenda K, et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol 1996; 22: 296–302CrossRefGoogle Scholar
  16. 16.
    Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93: 442–8PubMedCrossRefGoogle Scholar
  17. 17.
    Hinterleitner TA, Petritsch W, Aichbichler B, et al. Combination of cyclosporine, azathioprine and prednisolone. Z Gastroenterol 1997; 35: 603–8PubMedGoogle Scholar
  18. 18.
    Dejaco C, Gasche C, Reinisch W, et al. Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases. Wien Klin Wochenschr 1998; 110: 579–84PubMedGoogle Scholar
  19. 19.
    Gurudu SR, Griffel LH, Gialanella RJ, et al. Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results. J Clin Gastroenterol 1999; 29: 151–4PubMedCrossRefGoogle Scholar
  20. 20.
    Hermida-Rodriguez C, Cantero-Perona J, Garcia-Valriberas R, et al. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastro-enterology 1999; 46: 2265–8Google Scholar
  21. 21.
    Jewell DP, Lennard-Jones JE and the Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn’s disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994, 6: 499–505CrossRefGoogle Scholar
  22. 22.
    Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 1994; 330: 1846–51PubMedCrossRefGoogle Scholar
  23. 23.
    Stange EF, Modigliani R, Pena AS, European Study Group. European trial of cyclosporin in chronic active Crohn’s disease: a 12-month study. Gastroenterology 1995; 109: 774–82PubMedCrossRefGoogle Scholar
  24. 24.
    Sandborn WJ. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 48–63CrossRefGoogle Scholar
  25. 25.
    Mayer L, Xian Yang Yio, Lyn A, et al. Pathogenesis of inflammatory bowel disease: evolving concepts. Mt Sinai J Med 1996; 63: 202–9PubMedGoogle Scholar
  26. 26.
    Kovarik JM, Mueller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444–6PubMedCrossRefGoogle Scholar
  27. 27.
    Freeman D, Grant D, Levy G, et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17: 213–6PubMedCrossRefGoogle Scholar
  28. 28.
    Best W, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439–44PubMedGoogle Scholar
  29. 29.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 2: 1041PubMedCrossRefGoogle Scholar
  30. 30.
    Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301–4PubMedCrossRefGoogle Scholar
  31. 31.
    Fluckiger SS, Schmidt C, Meyer A, et al. Pharmacokinetics of orally administered cyclosporine in patients with Crohn’s disease. J Clin Pharmacol 1995; 35: 681–7PubMedGoogle Scholar
  32. 32.
    Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporin pharmacokinetics in renal transplant recipients treated with a micro-emulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505–11PubMedGoogle Scholar
  33. 33.
    Mueller EA, Kovarik JM, van Bree JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994; 11: 151–5PubMedCrossRefGoogle Scholar
  34. 34.
    Klauser RM, Irschik H, Kletzmayr J, et al. Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: does fat intake still matter? Transplant Proc 1997; 29: 3137–40PubMedCrossRefGoogle Scholar
  35. 35.
    Sandborn WJ, Strong RM, Forland SC, et al. The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration. J Clin Pharmacol 1991; 31: 76–80PubMedGoogle Scholar
  36. 36.
    Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4: 276–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Miriam Latteri
    • 1
  • Giulia Angeloni
    • 1
  • Nicola Gentiloni Silveri
    • 1
  • Raffaele Manna
    • 1
  • Giovanni Gasbarrini
    • 1
  • Pierluigi Navarra
    • 2
  1. 1.Institute of Internal MedicineCatholic University Medical SchoolRomeItaly
  2. 2.Institute of PharmacologyCatholic University Medical SchoolRomeItaly

Personalised recommendations